With obesity growing by leaps and bounds ,being responsible for millions of deaths either directly or indirectly through its complications like type 2 diabetes mellitus (T2M), Metabolic syndrome, various cancers there is need for medical answers to effectively combat it.With the pharmaceutical drugs getting developed and shunted out of market with undesirable side effects directions are being shifted towards more physiological methods using some plant extracts like thylakoids, various anthrocyanins etc to combat Insulin Syndrome ( IRS),T2DM similarly attention is being moved to modify gut microbiota with the use of probiotics and synbiotics.Till date most beneficial strains have been developed from Lactobacillus or Bifidobacteria.Although a promising strategy both in animal and human models still human trials have remained few with inconsistent results.Hence need for long term studies with more bacterial strains are desired to ensure Probiotics become an established method of treating obesity .Thus we carried out this review to understand what is the status of use of these Probiotics and synbiotics in human trials in patients having obesity ,T2DM, Hypertension, IRS, nonalcoholic fatty liver disease (NAFLD)and steatohepatitis.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: